JPMorgan發展中市場股票主動型ETF JADE 深 滬
已收盤 04-02 16:00:00 美东时间
66.54
-0.529
-0.79%
華盛通- 最 高66.54
- 今 開65.66
- 成交量 1164股
- 最 低 65.66
- 昨 收 67.0694
- 總市值 2661.60万
- 52周最高 73.5599
- 市盈率 靜 --
- 換手率 0.29%
- 52周最低 44.524
- 委 比 0.00%
- 總股本 40.00万
- 歷史最高 73.5599
- 量 比 0.67
- 振 幅 1.31%
- 歷史最低 40.7433
- 每 手 1
- 風險率 7.53%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多业聚医疗（6929.HK）：全年业绩再创新高，核心经营利润增20.2%，全球化与创新双轮驱动彰显韧性
2025年，全球医疗器械行业仍在关税扰动与地缘政治变局中艰难前行。业聚医疗却逆势交出一份硬核成绩单：收入与销量连续五年创下历史新高，核心经营利润同比猛增20....
03-16 08:51
BRIEF-Jade Biosciences Reports Fourth Quarter And Full Year 2025 Financial Results And Provides Corporate Update
BRIEF-Jade Biosciences Reports Fourth Quarter And Full Year 2025 Financial Results And Provides Corporate Update March 6 (Reuters) - Jade Biosciences Inc JBIO.O : JADE BIOSCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE JADE BIOSCIENCES INC: $336 MIL
03-06 20:27
Jade Biosciences Q4 R&D expenses rise to USD 28.5 million (+61.9%)
Jade Biosciences Q4 R&D expenses rise to USD 28.5 million (+61.9%) Jade Biosciences (JBIO) reported a FY 2025 net loss of USD 127.4 million and a Q4 2025 net loss of USD 31.9 million. FY 2025 R&D expenses were USD 93.1 million and FY 2025 G&A expenses were USD 20.4 million, while Q4 2025 R&D expense
03-06 20:00
Jade Biosciences Provides Pipeline Update: JADE101 Phase 1 Ongoing, Phase 2 In IgA Nephropathy Mid-26; JADE201 First-In-Human RA Study 2Q26; JADE301 Nominated With Phase 1 Planned 1H27
JADE101 Phase 1 healthy volunteer trial ongoing; biomarker-rich interim data expected in the first half of 2026 Phase 2 clinical trial of JADE101 in patients with IgA nephropathy expected to begin mid-2026;
01-05 20:14
BRIEF-Jade Biosciences Files For Offering Of 3.2 Million Shares Of Common Stock By Selling Stockholder- SEC Filing
Dec 22 (Reuters) - Jade Biosciences Inc JBIO.O: JADE BIOSCIENCES FILES FOR OFFERING OF 3.2 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDER- SEC FILING Source text: [ID:n0001193125-25-328848] Fur...
2025-12-23 06:54
RPT-ROI-Oil’s geopolitical premium vanished in 2025 - and may not return: Bousso
Repeats to additional subscribers without any changes. The opinions expressed here are those of the author, a columnist for Reuters. By Ron Bousso LONDON, Dec 22 (Reuters) - Global oil markets faced m...
2025-12-22 19:00
ROI-Oil’s geopolitical premium vanished in 2025 - and may not return: Bousso
The opinions expressed here are those of the author, a columnist for Reuters. By Ron Bousso LONDON, Dec 22 (Reuters) - Global oil markets faced multiple black swan events in 2025 – including the Israe...
2025-12-22 15:00
BRIEF-Jade Biosciences Announces $45 Million Private Placement
Dec 15 (Reuters) - Jade Biosciences Inc JBIO.O: JADE BIOSCIENCES ANNOUNCES $45 MILLION PRIVATE PLACEMENT Source text: ID:nGNX6CVfmk Further company coverage: JBIO.O ((Reuters.Briefs@thomsonreuters.com...
2025-12-15 20:10
BRIEF-Jade Biosciences Files For Offering Of Up To 16.1 Million Shares Of Common Stock By The Selling Stockholders - SEC Filing
Nov 14 (Reuters) - Jade Biosciences Inc JBIO.O: JADE BIOSCIENCES INC FILES FOR OFFERING OF UP TO 16.1 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING Source text: [ID:n00011931...
2025-11-15 05:17
Jade Road Investments Alters Board Appointment Plans
Jade Road Investments ( ($GB:JADE) ) has issued an update. Jade Road Investment...
2025-11-04 01:32
